What do next-gen biofuel companies offer the biotech investor ?
By John Hamer, PhD, Managing Director, Burrill & Company It’s interesting that JMP Healthcare Research’s Lazy Man Morning Notes carried the news of the Amyris IPO. Biotech investors will probably look seriously at this area, as much of the underlying technology (genomics, synthetic biology etc.) is shared with biotech and the first two companies’ out […]











